---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-26-000017"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T07:05:27.751414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF

## Summary
- Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.
- Data support basement membrane repair and AT2-to-AT1 epithelial cell transition, suggesting lung regeneration.
- GRI-0621 met primary safety endpoint and multiple secondary endpoints; exploratory FVC improved vs standard of care.
- CEO states data exceed expectations, reinforcing potential as a disease-modifying therapy for IPF.

## SEC filing metadata
- accession: 0001824293-26-000017
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000017/0001824293-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000017/val-20260128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-26-000017
- JSON: https://secwatch.observer/filing/0001824293-26-000017.json
- Plain text: https://secwatch.observer/filing/0001824293-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.